Comment from Janet Kornmann

Summary: Janet Kornmann, a board member of the National Drug and Alcohol Screening Association (NDASA), supports the FDA's proposal to expand 510(k) exemptions for certain medical devices used in workplace drug testing. She argues that the current clinical device framework is a structural mismatch for forensic testing and urges the FDA to eventually transfer oversight authority to SAMHSA and the NLCP.